merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>The skepticism arises because the drugs may not slow decline enough to be noticeable to patients or families, and the risks may outweigh the potential for a slight benefit.</answer>
<question_number>2</question_number>
<answer>The focus on anti-amyloid drugs might discourage patients from participating in trials for potentially better treatments, slowing progress in the field.</answer>
<question_number>3</question_number>
<answer>Dr. Greicius states there is no correlation between amyloid plaque removal and clinical response in individual subjects.</answer>
<question_number>4</question_number>
<answer>The higher rates of swelling and bleeding in the donanemab trial may raise concerns about Kisunla's safety compared to Leqembi.</answer>
<question_number>5</question_number>
<answer>The higher cost of Kisunla is justified by the expectation that patients can stop treatment after amyloid plaques are cleared, reducing overall cost and inconvenience.</answer>
<question_number>6</question_number>
<answer>The article suggests that the emphasis on anti-amyloid drugs might discourage patients from participating in trials for other treatments that could be better.</answer>
<question_number>7</question_number>
<answer>Kisunla can reduce inconvenience because patients can stop treatment after amyloid is cleared, unlike Leqembi, which requires ongoing dosing.</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels, suggesting earlier treatment is more effective.</answer>